This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (51)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mary-Claire Roghmann, MD

Arch Intern Med. 2000;160:1001-1004.

Background  The restriction of vancomycin hydrochloride use is recommended as a measure to decrease the emergence of vancomycin resistance in gram-positive organisms; however, vancomycin also is the treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. If vancomycin use is restricted to patients with documented infections due to methicillin-resistant organisms, then patients with MRSA infections may not initially receive vancomycin. This study was performed to determine factors that predict MRSA bacteremia and if ineffective empiric antibiotic therapy increased the risk of death in patients with S aureus bacteremia.

Methods  We conducted a retrospective cohort study of all patients with clinically significant S aureus bacteremia (132 episodes in 128 patients) diagnosed between October 1, 1995, and January 1, 1998, at an urban acute care Veterans Affairs medical center (approximately 200 acute care beds) in Baltimore, Md. During the study period, vancomycin was a restricted antibiotic. Empiric use had to be approved by an attending physician specializing in infectious diseases.

Results  Compared with patients who had methicillin-sensitive S aureus bacteremia, patients with MRSA bacteremia were significantly older (70 vs 58 years; P<.01), more likely to have a history of MRSA (47% vs 6%; P<.01) and a nosocomial infection (76% vs 50%; P<.01), and less likely to use injection drugs (8% vs 32%; P<.01). In addition, compared with patients who had methicillin-sensitive S aureus bacteremia, patients with MRSA bacteremia were significantly less likely (45% vs 98%; P<.01) to receive effective antibiotic therapy during the first 48 hours of hospitalization. However, the risk of death due to ineffective empiric therapy was less than 1 (relative risk, 0.82; 95% confidence interval, 0.36-1.88) and did not change significantly when adjusted for age, occurrence of sepsis, or nosocomial infection.

Conclusions  The results of this study support the safety of the restriction of vancomycin use in patients with clinically significant S aureus bacteremia. However, patients with a history of MRSA are more likely to have future MRSA infections and should receive empiric therapy using vancomycin for possible S aureus infections, particularly for nosocomial infections.

From the Veterans Affairs Maryland Health Care System and the Division of Hospital Epidemiology, Department of Medicine, University of Maryland School of Medicine, Baltimore.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock
Kumar et al.
Chest 2009;136:1237-1248.
ABSTRACT | FULL TEXT  

Staphylococcus aureus Infections in Hemodialysis: What a Nephrologist Should Know
Vandecasteele et al.
CJASN 2009;4:1388-1400.
ABSTRACT | FULL TEXT  

High Levels of mecA DNA Detected by a Quantitative Real-Time PCR Assay Are Associated with Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia
Ho et al.
J. Clin. Microbiol. 2009;47:1443-1451.
ABSTRACT | FULL TEXT  

Clinical implications of antimicrobial resistance for therapy
MacGowan and on behalf of the BSAC Working Parties on Resistanc
J Antimicrob Chemother 2008;62:ii105-ii114.
ABSTRACT | FULL TEXT  

Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome
Fang et al.
J Antimicrob Chemother 2006;57:511-519.
ABSTRACT | FULL TEXT  

Impact of Methicillin Resistance on Outcome of Staphylococcus aureus Ventilator-associated Pneumonia
Combes et al.
Am. J. Respir. Crit. Care Med. 2004;170:786-792.
ABSTRACT | FULL TEXT  

Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia
Kim et al.
J Antimicrob Chemother 2004;54:489-497.
ABSTRACT | FULL TEXT  

Rapid Molecular Diagnosis of Lactobacillus Bacteremia by Terminal Restriction Fragment Length Polymorphism Analysis of the 16S rRNA Gene
Christensen et al.
Clin Med Res 2004;2:37-45.
ABSTRACT | FULL TEXT  

Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia
Fowler et al.
Arch Intern Med 2003;163:2066-2072.
ABSTRACT | FULL TEXT  

Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients
Tumbarello et al.
J Antimicrob Chemother 2002;50:375-382.
ABSTRACT | FULL TEXT  

Staphylococcus Heterogeneously Resistant to Vancomycin in China and Antimicrobial Activities of Imipenem and Vancomycin in Combination against It
Benquan et al.
J. Clin. Microbiol. 2002;40:1109-1112.
ABSTRACT | FULL TEXT  

Rapid Identification of Methicillin-Resistant Staphylococcus aureus from Positive Blood Cultures by Real-Time Fluorescence PCR
Tan et al.
J. Clin. Microbiol. 2001;39:4529-4531.
ABSTRACT | FULL TEXT  

Methicillin-Resistant Staphylococcus aureus: Comparison of Susceptibility Testing Methods and Analysis of mecA-Positive Susceptible Strains
Sakoulas et al.
J. Clin. Microbiol. 2001;39:3946-3951.
ABSTRACT | FULL TEXT  

Methicillin-Susceptible Staphylococcus aureus: Believe It, or Not
Sakoulas et al.
Arch Intern Med 2001;161:1237-1238.
FULL TEXT  

Does Adequacy of Empiric Therapy for MRSA Bacteremia Matter?
JWatch Infect. Diseases 2000;2000:4-4.
FULL TEXT